51视频

01/16/2019
By Edwin L. Aguirre

Tyler Iorizzo, a Ph.D. student in the Department of Physics and Applied Physics, has won international recognition for his contribution in developing an imaging device that could lead to improved diagnosis and treatment of certain skin cancers.

Iorizzo was one of seven university researchers from North America and Europe who received an , one of the world鈥檚 leading suppliers of high-precision optics for the optical industry.

Iorizzo is part of a team that developed a device called an optical polarization imager, or OPI, that could help doctors identify the margins of prior to surgery, allowing them to remove the malignant tumor with more precision and resulting in less complication and quicker recovery for the patient.

鈥淚鈥檓 thrilled and very honored to win this international award,鈥� says Iorizzo, who conducts his research at the university鈥檚 Advanced Biophotonics Laboratory. 鈥淚鈥檓 glad to be able to help people. Imaging with the OPI is completely harmless and noninvasive. It doesn鈥檛 use X-ray or high-intensity laser so it鈥檚 perfectly safe for the patient and the doctor.鈥�

鈥淐urrently, there is no comparable tool available in the market,鈥� says Assoc. Prof. of Physics Anna Yaroslavsky, who is the director and founder of the Advanced Biophotonics Laboratory and inventor of the OPI technology. She is also Iorizzo鈥檚 thesis adviser.

鈥淪urgeons basically look at the outline of a cancerous lesion visually and, based on their experience and training, decide where and how much tissue to cut. In many cases, errors can arise because they can鈥檛 see the margins of the tumor very well,鈥� she says.

Yaroslavsky says OPI鈥檚 rapid, easy-to-use technology produces images that are easy to interpret and don鈥檛 require extensive processing to analyze.

鈥淥perating the OPI doesn鈥檛 require extensive training and doesn鈥檛 disrupt clinical workflow,鈥� she says. 鈥淚t offers a field of view several centimeters across and tens-of-micron resolution at unparalleled low cost.鈥�

Iorizzo adds that imaging with the OPI is easier for people to tolerate. 鈥淭he procedure produces better cosmetic outcome and repair of the incision site, as well as lower medical cost,鈥� he says.

Going More than Skin-deep

According to the 鈥淎merican Journal of Preventive Medicine,鈥� is the most common form of cancer in the United States, with about 3 million to 5 million new lesions being diagnosed every year. Approximately 3,000 people die from the disease annually. Statistically, 1 in 4 fair-skinned people may develop NMSC, and the cost of treatment is nearly $5 billion a year.

NMSC refers to types of cancer that occur in the skin that are not melanoma, which primarily affects the pigment-producing melanocyte cells. NMSC includes the common basal cell carcinoma and squamous cell carcinoma.

The most effective treatment for NMSC usually involves Mohs surgery, in which the cancerous tumor is removed by excising the tissue layer by layer, with each layer examined under a microscope to help map the diseased area. The goal is to completely remove the tumor while preserving as much of the surrounding healthy tissue as possible. While the procedure is effective, it is time-consuming, labor-intensive and costly.

鈥淭umor boundaries associated with NMSC are difficult to detect based on visual assessment alone,鈥� notes Iorizzo. 鈥淭his results in inefficient removal of the cancerous tissue, which can lead to recurrence of the tumor.鈥�

The OPI uses a couple of special optical filters (called crossed linear polarizers), a high-resolution CCD camera and a ring-shaped illuminator for wide-field imaging of the skin at resolutions of up to 12 micrometers (millionths of a meter). It utilizes visible light at several wavelengths with polarization to take images of the skin at certain depths to emphasize structures such as collagen, blood vessels and any melanin (pigmented) patches that may be present.

鈥淥ur optical imaging system can identify disruptions in the skin鈥檚 collagen structure caused by the tumor, allowing for precise in-vivo mapping of the skin cancer before surgery,鈥� Iorizzo says.

Iorizzo鈥檚 Silver Prize award consists of $7,500 worth of Edmund Optics products that will be used in the Advanced Biophotonics Lab.

Yaroslavsky has several awarded and pending patents for the OPI. She and her team, which also includes physics Ph.D. students Peter Jermain and Androniki Mitrou, will be applying for industry and federal funding to continue and expand the clinical trials.

鈥淥ur goal is to commercialize the technology by licensing it to an existing medical device manufacturer and setting up our own spinoff company. We are working on a prototype right now. The commercial version is going to be much smaller and more compact,鈥� she says.

Aside from skin cancer, the Advanced Biophotonics Lab is also conducting research on breast, brain and kidney cancers in collaboration with Harvard Medical School, Massachusetts General Hospital and UMass Medical School. The researchers鈥� work is supported by the U.S. National Institutes of Health, the American Society for Laser Medicine & Surgery and the University of Massachusetts.